OFS Capital Corporation - 7.50% Notes due 2028 (OFSSO)
Live price chart, market sentiment, and community perspectives for OFS Capital Corporation - 7.50% Notes due 2028 (NASDAQ: OFSSO).
Live price chart, market sentiment, and community perspectives for OFS Capital Corporation - 7.50% Notes due 2028 (NASDAQ: OFSSO).
On our desk, the issuance of the 7.50% notes due 2028 (OFSSO) is viewed primarily as a calculated move to execute a leverage-neutral refinancing. By utilizing proceeds to redeem maturing or existing lower-rate notes—such as the 4.75% notes due 2026—management is actively working to manage its debt maturity profile. However, market participants are keeping a close eye on the broader financial health, especially given that NAV dipped from $10.91 to $10.17 and non-accrual loans ticked up to $23.1 million, or roughly 6.2% of total investments. Sentiment reflects cautious observation regarding how effectively these capital structure adjustments will offset underlying asset quality pressures.
Looking at the credit profile from a risk management standpoint, OFS Capital maintains a predominantly floating-rate loan portfolio at roughly 89%, which theoretically offers a cushion in varying interest rate environments. Yet, the presence of non-accrual loans at over 6% of total investments introduces notable credit risk that investors must weigh against the 7.50% coupon offered by the notes maturing in July 2028. Regulatory asset coverage sitting at 157% provides some context on their leverage constraints, making continuous monitoring of portfolio company EBITDA and cash flows essential for noteholders.
In evaluating the operational mechanics of OFS Capital Corporation, our technical review focuses heavily on their underwriting criteria within the lower middle market. They target companies with annual EBITDA between $5 million and $50 million, deploying $3 to $35 million in senior secured and unitranche structures. When analyzing debt offerings like OFSSO, analysts must reconcile their stated strategy of avoiding operational turnarounds with recent periods where net losses on investments and declining net investment income per share—down to $0.22 in Q3 from $0.25 in Q2—highlight the intrinsic volatility of direct lending portfolios.
Explore plasma cleansing, somatic organ swaps, and BCI.